Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Background: Patients (pts) with cancer have increased morbidity and mortality associated with the development of SARS-Co-V2 infection. The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy with 95-97% prevention of severe COVID-19 disease and development of protective antibody tit...

Descripción completa

Detalles Bibliográficos
Autores principales: Goel, Shipra, Gu, Juan J., Torka, Pallawi, Mavis, Cory, Sundaram, Suchitra, Neiders, Mirdza, Suresh, Lakshmanan, Shen, Long, Ramsperger, Vince, Griffiths, Elizabeth A., Segal, Brahm, Hernandez-Ilizaliturri, Francisco J., Ghione, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
622.Lymphomas: Translational-Non-Genetic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701506/
http://dx.doi.org/10.1182/blood-2021-152738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701506/
http://dx.doi.org/10.1182/blood-2021-152738

Ejemplares similares